Sigurdsson, Einar M.
Einar M Sigurdsson
Einar Már Sigurðsson 1965-
Sigurdsson, Einar M. 1965-
VIAF ID: 163488328 (Personal)
Permalink: http://viaf.org/viaf/163488328
Preferred Forms
-
-
100 0 _ ‡a Einar M Sigurdsson
-
100 1 _ ‡a Sigurdsson, Einar M
-
-
100 1 _ ‡a Sigurdsson, Einar M.
-
-
100 1 _ ‡a Sigurdsson, Einar M.
-
-
-
-
100 1 _ ‡a Sigurdsson, Einar M.
-
-
-
100 1 _ ‡a Sigurdsson, Einar M. ‡d 1965-
4xx's: Alternate Name Forms (5)
5xx's: Related Names (2)
Works
Title | Sources |
---|---|
Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy. |
![]() |
Áhrif þriggja extrakta úr brjóstagrasi (Thalictrum alpinum) og usnic sýru úr hreindýramosa (Cladonia arbuscula) á frumur í rækt |
![]() |
Alzheimer's disease: challenges ahead |
![]() |
Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds. |
![]() |
Amyloid-beta injection in rat amygdala alters tau protein but not mRNA expression. |
![]() |
Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. |
![]() |
Amyloid-_ deposition in rat brain : histopathological and functional sequelae |
![]() |
Amyloid fibril formation by macrophage migration inhibitory factor |
![]() |
Amyloid proteins : methods and protocols |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
Anti-prion antibodies for prophylaxis following prion exposure in mice |
![]() |
Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance. |
![]() |
An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. |
![]() |
beta-Amyloid 25-35 and/or quinolinic acid injections into the basal forebrain of young male Fischer-344 rats: behavioral, neurochemical and histological effects. |
![]() |
Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy |
![]() |
Bóluefni gegn riðuveiki og Alzheimer? |
![]() |
Conformation as therapeutic target in the prionoses and other neurodegenerative conditions |
![]() |
Distinct properties of wild-type and the amyloidogenic human cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type |
![]() |
Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory |
![]() |
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) |
![]() |
Harnessing the immune system for treatment and detection of tau pathology. |
![]() |
High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice. |
![]() |
Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau |
![]() |
Histological staining of amyloid-β in mouse brains |
![]() ![]() |
Immunization delays the onset of prion disease in mice. |
![]() |
Immunization treatment approaches in Alzheimer's and prion diseases. |
![]() |
Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice |
![]() |
Immunotherapy for conformational diseases. |
![]() |
In Vivo Evaluation of Neuronal Transport in Murine Models of Neurodegeneration Using Manganese-Enhanced MRI |
![]() |
In Vivo Imaging of Tauopathy in Mice |
![]() |
In vivo reversal of amyloid-beta lesions in rat brain. |
![]() |
Infectivity of amyloid diseases |
![]() |
Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach |
![]() |
Live Imaging of Pathological Tau Protein and Tau Antibodies in a Neuron-Like Cellular Model |
![]() |
Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model |
![]() |
Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging |
![]() |
Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging |
![]() |
Mucosal vaccination delays or prevents prion infection via an oral route. |
![]() |
New directions towards safer and effective vaccines for Alzheimer's disease. |
![]() |
A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice |
![]() |
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain |
![]() |
Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology |
![]() |
Promising developments in prion immunotherapy |
![]() |
Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice. |
![]() |
en scientific article |
![]() |
Specific amyloid β clearance by a catalytic antibody construct |
![]() |
Structural characterization of monoclonal antibodies targeting C-terminal Ser404 region of phosphorylated tau protein |
![]() |
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. |
![]() |
Tabibi Sabbu |
![]() |
Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy |
![]() |
Tau Antibody Structure Reveals a Molecular Switch Defining a Pathological Conformation of the Tau Protein. |
![]() |
Tau immunotherapy and imaging. |
![]() |
Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments. |
![]() |
Tau-targeting therapies for Alzheimer disease |
![]() |
Therapeutic applications of antibodies in non-infectious neurodegenerative diseases |
![]() |
Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology |
![]() |
Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages |
![]() |